Immunogenicity and safety of biological E's 14-valent pneumococcal conjugate vaccine (PNEUBEVAX 14®) administered in a 2p + 1 schedule to healthy infants: a multicenter, randomized, active controlled, single-blind, phase III trial
一项多中心、随机、活性对照、单盲、III期临床试验，旨在评估生物制品公司E研发的14价肺炎球菌结合疫苗（PNEUBEVAX 14®）在健康婴儿中采用2p+1接种程序时的免疫原性和安全性。
期刊:Lancet Regional Health - Southeast Asia
影响因子:6.2
doi:10.1016/j.lansea.2026.100746
Thuluva, Subhash; Matur, Ramesh V; Gunneri, Subbareddy; Ningaiah, Siddalingaiah; Yerroju, Vijay; Mogulla, Rammohan Reddy; Dhar, Chirag; Thammireddy, Kamal; Paliwal, Piyush; Kawade, Anand; Nanjappa, Pradeep; Pramod, Jog; Narang, Manish; Chakravarthy, Bheemisetty S; Virupakashappa, Prashanth M
